CoChat

Inhibition of FAK kinase activity preferentially targets cancer stem cells

Open access
Kolev, Vihren N., Tam, Winnie F., Wright, Quentin G., McDermott, Sean P., Vidal, Christian M., Shapiro, Irina M., Xu, Qunli, Wicha, Max S., Pachter, Jonathan A., Weaver, David T. · 2017 · Oncotarget
Cited by 73

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Vihren N. Kolev 1 , Winnie F. Tam 1 , Quentin G. Wright 1 , Sean P. McDermott 2 , Christian M. Vidal 1 , Irina M. Shapiro 1 , Qunli Xu 1 , Max S. Wicha 2 , Jonathan A. Pachter 1 and David T. Weaver 1 1 Verastem, Inc., Needham, MA, USA 2 Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA Correspondence to: David T. Weaver, email: dweaver@verastem.com Jonathan A. Pachter, email: jpachter@verastem.com Keywords: cancer stem cells, FAK, focal adhesion kinase, VS-4718, VS-6063 Received: February 02, 2017 Accepted: May 06, 2017 Published: June 16, 2017 ABSTRACT Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical challenges to cancer treatment. VS-4718 and VS-6063 are potent inhibitors of focal adhesion kinase (FAK), a non-receptor tyrosine kinase that mediates cell signals transmitted by integrins and growth factor receptors. We report here that inhibition of FAK kinase activity by VS-4718 or VS-6063 preferentially targets CSCs, as demonstrated by a panel of orthogonal CSC assays in cell line models and surgically resected primary breast tumor specimens cultured ex vivo . Oral administration of VS-4718 or VS-6063 to mice bearing xenograft models of triple-negative breast cancer (TNBC) significantly reduced the proportion of CSCs in the tumors, as evidenced by a reduced tumor-initiating capability upon re-implantation in limiting dilutions of cells prepared from these tumors. In contrast, the cytotoxic chemotherapeutic agents, paclitaxel and carboplatin, enriched for CSCs, consistent with previous reports that these cytotoxic agents preferentially target non-CSCs. Importantly, VS-4718 and VS-6063 attenuated the chemotherapy-induced enrichment of CSCs in vitro and delayed tumor regrowth following cessation of chemotherapy. An intriguing crosstalk between FAK and the Wnt/β-catenin pathway was revealed wherein FAK inhibition blocks β-catenin activation by reducing tyrosine 654 phosphorylation of β-catenin. Furthermore, a constitutively active mutant form of β-catenin reversed the preferential targeting of CSCs by FAK inhibition, suggesting that this targeting is mediated, at least in part, through attenuating β-catenin activation. The preferential targeting of cancer stem cells by FAK inhibitors provides a rationale for the clinical development of FAK inhibitors aimed to increase durable responses for cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.18517

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 73

Metadata

Authors
Kolev, V. N., Tam, W. F., Wright, Q. G., McDermott, S. P., Vidal, C. M., Shapiro, I. M., Xu, Q., Wicha, M. S., Pachter, J. A., & Weaver, D. T.
Venue
Oncotarget
Published
2017-06-16
Volume
8
Issue
31
Pages
51733-51747
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2626577233
Cited by
73
References
5
FWCI
4.52
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.